Fig. 1

Pathological characterization of a novel animal model of Alzheimer’s disease. a and c For detection of amyloid plaques, hippocampal regions of ADLP mice were immunostained with the biotin-4G8 antibody at 4-, 7-, and 10-month-old. The percentage of amyloid plaques area was not significantly different between ADLP^APP/PS1 and ADLP^APT mice (Student’s t-test, n = 3–4 per group). Scale bar represents 200 μm. b and d) The hippocampal CA1 layer of ADLP mice was stained with the AT8 antibody against phosphorylated tau (Ser202/Thr205). A significant increase in AT8 immunoreactivity was observed in ADLP^APT mice compared with age-matched ADLP^Tau mice (Student’s t-test, n = 3–4 per group). Scale bar represents 200 μm. e Sarkosyl-insoluble tau fractions from 7 and 10 months ADLP mice hippocampus were analyzed by western blot analysis using human tau specific antibody (Tau13). f Each distinct size of sarkosyl-insoluble tau was quantified in 10 months old ADLP^Tau and ADLP^APT mice (Chi-square test; n = 6 mice per genotypes). g The CA1 pyramidal neurons of ADLP mice were stained with anti-NeuN antibody to determine degrees of neuronal loss. Scale bars represents 100 μm or 50 μm (enlarged figures). h Quantification of the number of CA1 neurons in 7- and 10-month-old ADLP mouse model (one-way ANOVA in each age of ADLP mouse model). i ADLP model mice showed memory impairment compared with wild-type mice, which examined by the Y-maze test (one-way ANOVA in each age of ADLP mouse model, n = 9–11 per group). Results are expressed as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001